Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Sell
46
ARTV Quote, Financials, Valuation and Earnings
Last price:
$4.00
Seasonality move
:
-67.7%
Day range:
$3.89 - $4.14
52-week range:
$1.47 - $7.36
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
46.79x
P/B ratio:
0.76x
Volume:
40K
Avg. volume:
194.9K
1-year change:
-0.25%
Market cap:
$98.2M
Revenue:
$251K
EPS (TTM):
-$3.25
Analysts' Opinion
-
Consensus RatingArtiva Biotherapeutics, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 5 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $17.00, Artiva Biotherapeutics, Inc. has an estimated upside of 325% from its current price of $4.00.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $10.00 representing 100% downside risk from its current price of $4.00.
Fair Value
-
According to the consensus of 5 analysts, Artiva Biotherapeutics, Inc. has 325% upside to fair value with a price target of $17.00 per share.
ARTV vs. S&P 500
-
Over the past 5 trading days, Artiva Biotherapeutics, Inc. has overperformed the S&P 500 by 0.7% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Artiva Biotherapeutics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Artiva Biotherapeutics, Inc. revenues have been falling on a year-over-year basis for 5 quarters in a row. In the most recent quarter Artiva Biotherapeutics, Inc. reported revenues of --.
Earnings Growth
-
Artiva Biotherapeutics, Inc. earnings have been falling on a year-over-year basis for 5 quarters in a row. In the most recent quarter Artiva Biotherapeutics, Inc. reported earnings per share of -$0.88.
Enterprise value:
-13.1M
EV / Invested capital:
--
Price / LTM sales:
46.79x
EV / EBIT:
--
EV / Revenue:
31.29x
PEG ratio (5yr expected):
-0.07x
EV / Free cash flow:
0.17x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$2.5M
Return On Assets:
-41.91%
Net Income Margin (TTM):
-1351.52%
Return On Equity:
-47.44%
Return On Invested Capital:
-43.85%
Operating Margin:
-5773.71%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $30.4M | $2.6M | -- | -- | -- | |
| Gross Profit | $29M | $190K | -$2.5M | -$627K | -$662K | |
| Operating Income | -$30.6M | -$61.4M | -$86.3M | -$18.5M | -$22.9M | |
| EBITDA | -$29.2M | -$59M | -$83.8M | -$17.9M | -$22.2M | |
| Diluted EPS | -$1.82 | -$2.77 | -$3.25 | -$0.72 | -$0.88 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $171.5M | -- | -- | $150.6M | $129.5M | |
| Total Assets | $178.2M | -- | -- | $225.6M | $148.9M | |
| Current Liabilities | $15.6M | -- | -- | $13.3M | $11.1M | |
| Total Liabilities | $257.4M | -- | -- | $24.6M | $19.6M | |
| Total Equity | -$79.2M | -- | -- | $201M | $129.2M | |
| Total Debt | -- | -- | -- | $11.4M | $8.6M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$46.4M | -$51.1M | -$76.7M | -$11.6M | -$19.2M | |
| Cash From Investing | -$23.9M | -$122.2M | $46.4M | -$130.6M | $16.3M | |
| Cash From Financing | $23.1M | $163.2M | $100K | $163.9M | -$37K | |
| Free Cash Flow | -$49.6M | -$52.3M | -$78.9M | -$11.7M | -$19.8M | |
ARTV
Sector
Market Cap
$98.2M
$24M
Price % of 52-Week High
54.35%
48.29%
Dividend Yield
0%
0%
Shareholder Yield
0.63%
-1.62%
1-Year Price Total Return
-0.25%
-22.92%
Beta (5-Year)
--
0.500
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$3.92
200-day SMA
Buy
Level
$3.11
Bollinger Bands (100)
Buy
Level
3.1 - 4.64
Chaikin Money Flow
Sell
Level
-29.2M
20-day SMA
Sell
Level
$4.26
Relative Strength Index (RSI14)
Sell
Level
46.10
ADX Line
Sell
Level
23.07
Williams %R
Neutral
Level
-70.9924
50-day SMA
Sell
Level
$4.20
MACD (12, 26)
Sell
Level
-0.13
25-day Aroon Oscillator
Sell
Level
-76
On Balance Volume
Neutral
Level
130M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (4.6956)
Sell
CA Score
(Annual)
Level (-1.1948)
Buy
Beneish M-Score
(Annual)
Level (-33.4218)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (3.4588)
Buy
Piotroski F Score
(Annual)
Level (4)
Sell
Quality Ratio Score
Level (1)
Buy
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Artiva Biotherapeutics, Inc. operates as a biotechnology company for the treatment of hematologic cancers. It offers NK cell therapies for cancer. The company was founded by Thomas J. Farrell in 2019 and is headquartered in San Diego, CA.
Stock Forecast FAQ
In the current month, ARTV has received 5 Buy ratings 0 Hold ratings, and 0 Sell ratings. The ARTV average analyst price target in the past 3 months is $17.00.
-
Where Will Artiva Biotherapeutics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Artiva Biotherapeutics, Inc. share price will rise to $17.00 per share over the next 12 months.
-
What Do Analysts Say About Artiva Biotherapeutics, Inc.?
Analysts are divided on their view about Artiva Biotherapeutics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Artiva Biotherapeutics, Inc. is a Sell and believe this share price will drop from its current level to $10.00.
-
What Is Artiva Biotherapeutics, Inc.'s Price Target?
The price target for Artiva Biotherapeutics, Inc. over the next 1-year time period is forecast to be $17.00 according to 5 Wall Street analysts, 5 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is ARTV A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Artiva Biotherapeutics, Inc. is a Buy. 5 of 5 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of ARTV?
You can purchase shares of Artiva Biotherapeutics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Artiva Biotherapeutics, Inc. shares.
-
What Is The Artiva Biotherapeutics, Inc. Share Price Today?
Artiva Biotherapeutics, Inc. was last trading at $4.00 per share. This represents the most recent stock quote for Artiva Biotherapeutics, Inc.. Yesterday, Artiva Biotherapeutics, Inc. closed at $4.00 per share.
-
How To Buy Artiva Biotherapeutics, Inc. Stock Online?
In order to purchase Artiva Biotherapeutics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get ARTV Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
ARTV
Sector
P/E ratio
--
23.44x
PEG ratio
-0.07x
-0.01x
P/B ratio
0.76x
1.73x
Price / LTM sales
46.79x
1.51x
Growth Metrics
ARTV
Sector
Revenue growth
126.13%
3.31%
Earnings growth
-22.24%
10.7%
Revenue (5-year growth)
--
6.28%
Earnings forecast
-$0.80
-$0.19
Profitability
ARTV
Sector
Profitability FY 2024
-$2.2M
$2.6M
Return on invested capital
-43.85%
-33.62%
Return on assets
-41.91%
-29.74%
Return on equity
-47.44%
-39.33%
Earnings Date
Last Earnings Date
Aug
7
Next Earnings Date
Feb
15
Estimated Next Earnings Date
May
17
Balance Sheet
ARTV
Sector
Total cash
$123M
$25M
Short term investments
$145.2M
$23.9M
Total assets
$209.6M
$71.9M
Long term debt
$8.6M
$2.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Is Sandisk The Next Big Memory Stock?
Computer memory manufacturer Sandisk (NASDAQ:SNDK) has quietly been one of…
Stock Ideas
Buy
51
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Sell
43
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 34x
Sell
44
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Buy
77
CPS alert for Feb 14
Cooper-Standard Holdings, Inc. [CPS] is up 32.06% over the past day.
Buy
58
TPH alert for Feb 14
Tri Pointe Homes, Inc. [TPH] is up 26.83% over the past day.
Sell
20
IRON alert for Feb 14
Disc Medicine, Inc. [IRON] is down 21.88% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
